Publicaciones en las que colabora con Emilio Fernández-Espejo (15)

2022

  1. Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease

    Clinical Parkinsonism and Related Disorders, Vol. 7

2021

  1. ATP13A2 levels in serum and cerebrospinal fluid in patients with idiopathic Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 88, pp. 3-9

  2. Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson's disease, and correlates with levodopa equivalent daily dose

    Brain Research, Vol. 1761

2018

  1. Oleoylethanolamide and Palmitoylethanolamide Protect Cultured Cortical Neurons Against Hypoxia

    Cannabis and Cannabinoid Research, Vol. 3, Núm. 1, pp. 171-178

2014

  1. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 3, pp. 455-468

2013

  1. Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism

    Addiction Biology, Vol. 18, Núm. 1, pp. 78-87

2010

  1. Effects of the endogenous PPAR-α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice

    Synapse, Vol. 64, Núm. 5, pp. 379-389

2009

  1. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons

    Neuropharmacology, Vol. 56, Núm. 3, pp. 653-664

  2. Role of cannabis and endocannabinoids in the genesis of schizophrenia

    Psychopharmacology, Vol. 206, Núm. 4, pp. 531-549

  3. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine

    Neuroscience, Vol. 164, Núm. 2, pp. 667-675

2008

  1. Expression and function of CB1 receptor in the rat striatum: Localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors

    Neuropsychopharmacology, Vol. 33, Núm. 7, pp. 1667-1679

2007

  1. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies

    European Journal of Pharmacology, Vol. 559, Núm. 2-3, pp. 180-183

2005

  1. Acute Δ9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion

    Pharmacology Biochemistry and Behavior, Vol. 81, Núm. 1, pp. 71-77

  2. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

    Neurobiology of Disease, Vol. 18, Núm. 3, pp. 591-601

2004

  1. Experimental Parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: A modulator of endocannabinoid function

    Neuropsychopharmacology, Vol. 29, Núm. 6, pp. 1134-1142